SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                                    FORM 8-K
                                 CURRENT REPORT
                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

                        Date of report (Date of earliest
                                event reported):
                                February 18, 2003
                              CITA BIOMEDICAL, INC.

             (Exact name of registrant as specified in its charter)



              Delaware                                  93-0962072
              --------                                  ----------
(State or other jurisdiction of             (I.R.S. Employer Identification No.)
incorporation or organization)

             9025 Wilshire Blvd. Suite 301, Beverly Hills, CA 90211
               (Address of principal executive offices) (Zip code)
                                 (310) 550-4971
                         (Registrant's telephone number,
              including area code) (Former name, former address and
               former fiscal year, if changed since last report.)

ITEM 5. OTHER EVENTS.

CITA Biomedical,  Inc. ("CITA"  "Company")  reported on February 12, 2003 it had
received  a notice  of  default  from CITA SL for their  license  agreement  for
Detoxification and NeuroAdaptation  ("DNA") Intellectual  Property developed for
the purpose of "resetting" the brain function of a habituated alcohol or cocaine
user to its  pre-habituation  state.  CITA stated in the 8K, dated  February 12,
2003,  that CITA will  require  significant  capital  investment  in order to be
granted  use of this  license  agreement  beyond May 9, 2003 and to return to an
exclusive  basis.  The Company  wants to state clearly there is no agreement for
the DNA  Intellectual  Property  license  to be  extended  beyond  May 9,  2003.
However, there are continuing discussions with CITA SL, but no assurances can be
made  that if CITA  were  to  raise  significant  capital  the DNA  Intellectual
Property license would be extended or the license would be granted for exclusive
use by CITA. In this interim period,  the Company plans to  aggressively  market
and sale its proprietary  UROD(TM) treatment process to raise additional working
capital.

If CITA is unsuccessful in raising additional capital and is unable to negotiate
an extension for the DNA  Intellectual  Property  license in all probability the
Company will have to file for Chapter 11 bankruptcy  protection in the very near
future.

This release contains projections and other forward-looking statements regarding
future events and the future  financial  performance  of CITA that involve risks
and uncertainties.  Readers are cautioned that these forward-looking  statements
are only  predictions  and may differ  materially  from actual  future events or
results.  Readers  are  referred  to the  documents  filed by CITA with the SEC,
specifically  the most recent reports on Form 10-KSB and 10-QSB,  each as it may
be amended from time to time,  which identify  important risk factors that could
cause  actual  results to differ  from those  contained  in the  forward-looking
statements.  The financial  information contained in this release should be read
in  conjunction  with the  consolidated  financial  statements and notes thereto
included in CITA's most recent  reports on Form 10-KSB and Form 10-QSB,  each as
it may be amended from time to time.  CITA's results of operations for the three
and nine months  ended  September  30, 2002 are not  necessarily  indicative  of
CITA's operating results for future periods.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

None required.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

CITA BIOMEDICAL, INC.
Dated: February 18, 2003                                By: /s/ Joseph Dunn
                                                            ---------------
                                                            Joseph Dunn
[{"type": "8-K", "sequence": "1", "filename": "cita8k.txt", "description": "8K FOR CITA BIOMEDICAL", "secsgml_size_bytes": 4253}]
{"company-data": {"conformed-name": "CITA BIOMEDICAL INC", "cik": "0000700890", "assigned-sic": "8090", "irs-number": "930962072", "state-of-incorporation": "CO", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-10965", "film-number": "03571081"}, "business-address": {"street1": "9025 WILSHIRE BLVD", "street2": "SUITE 301", "city": "BEVERLY HILLS", "state": "CA", "zip": "90211", "phone": "7196335301"}, "mail-address": {"street1": "9025 WILSHIRE BLVD", "street2": "SUITE 301", "city": "BEVERLY HILLS", "state": "CA", "zip": "90211"}, "former-company": [{"former-conformed-name": "BLUE GRASS BREEDERS INC", "date-changed": "19930701"}, {"former-conformed-name": "SOUTHWESTERN ENVIRONMENTAL CORP", "date-changed": "19930719"}]}
SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                                    FORM 8-K
                                 CURRENT REPORT
                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

                        Date of report (Date of earliest
                                event reported):
                                February 18, 2003
                              CITA BIOMEDICAL, INC.

             (Exact name of registrant as specified in its charter)

              Delaware                                  93-0962072
              --------                                  ----------
(State or other jurisdiction of             (I.R.S. Employer Identification No.)
incorporation or organization)

             9025 Wilshire Blvd. Suite 301, Beverly Hills, CA 90211
               (Address of principal executive offices) (Zip code)
                                 (310) 550-4971
                         (Registrant's telephone number,
              including area code) (Former name, former address and
               former fiscal year, if changed since last report.)

ITEM 5. OTHER EVENTS.

CITA Biomedical,  Inc. ("CITA"  "Company")  reported on February 12, 2003 it had
received  a notice  of  default  from CITA SL for their  license  agreement  for
Detoxification and NeuroAdaptation  ("DNA") Intellectual  Property developed for
the purpose of "resetting" the brain function of a habituated alcohol or cocaine
user to its  pre-habituation  state.  CITA stated in the 8K, dated  February 12,
2003,  that CITA will  require  significant  capital  investment  in order to be
granted  use of this  license  agreement  beyond May 9, 2003 and to return to an
exclusive  basis.  The Company  wants to state clearly there is no agreement for
the DNA  Intellectual  Property  license  to be  extended  beyond  May 9,  2003.
However, there are continuing discussions with CITA SL, but no assurances can be
made  that if CITA  were  to  raise  significant  capital  the DNA  Intellectual
Property license would be extended or the license would be granted for exclusive
use by CITA. In this interim period,  the Company plans to  aggressively  market
and sale its proprietary  UROD(TM) treatment process to raise additional working
capital.

If CITA is unsuccessful in raising additional capital and is unable to negotiate
an extension for the DNA  Intellectual  Property  license in all probability the
Company will have to file for Chapter 11 bankruptcy  protection in the very near
future.

This release contains projections and other forward-looking statements regarding
future events and the future  financial  performance  of CITA that involve risks
and uncertainties.  Readers are cautioned that these forward-looking  statements
are only  predictions  and may differ  materially  from actual  future events or
results.  Readers  are  referred  to the  documents  filed by CITA with the SEC,
specifically  the most recent reports on Form 10-KSB and 10-QSB,  each as it may
be amended from time to time,  which identify  important risk factors that could
cause  actual  results to differ  from those  contained  in the  forward-looking
statements.  The financial  information contained in this release should be read
in  conjunction  with the  consolidated  financial  statements and notes thereto
included in CITA's most recent  reports on Form 10-KSB and Form 10-QSB,  each as
it may be amended from time to time.  CITA's results of operations for the three
and nine months  ended  September  30, 2002 are not  necessarily  indicative  of
CITA's operating results for future periods.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

None required.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

CITA BIOMEDICAL, INC.
Dated: February 18, 2003                                By: /s/ Joseph Dunn
                                                            ---------------
                                                            Joseph Dunn